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Impact of deploying multiple point-of-care tests
with a ‘sample ﬁrst’ approach on a sexual health
clinical care pathway. A service evaluation
Emma M Harding-Esch,1,2 Achyuta V Nori,1,3 Aseel Hegazi,3 Marcus J Pond,1
Olanike Okolo,3 Anthony Nardone,2 Catherine M Lowndes,2 Phillip Hay,1,3
S Tariq Sadiq1,3
ABSTRACT
Objectives To assess clinical service value of STI point-
of-care test (POCT) use in a ‘sample ﬁrst’ clinical
pathway (patients providing samples on arrival at clinic,
before clinician consultation). Speciﬁc outcomes were:
patient acceptability; whether a rapid nucleic acid
ampliﬁcation test (NAAT) for Chlamydia trachomatis/
Neisseria gonorrhoeae (CT/NG) could be used as a POCT
in practice; feasibility of non-NAAT POCT implementation
for Trichomonas vaginalis (TV) and bacterial vaginosis
(BV); impact on patient diagnosis and treatment.
Methods Service evaluation in a south London sexual
health clinic. Symptomatic female and male patients and
sexual contacts of CT/NG-positive individuals provided
samples for diagnostic testing on clinic arrival, prior to
clinical consultation. Tests included routine culture and
microscopy; CT/NG (GeneXpert) NAAT; non-NAAT POCTs
for TV and BV.
Results All 70 (35 males, 35 females) patients approached
participated. The ‘sample ﬁrst’ pathway was acceptable, with
>90% reporting they were happy to give samples on arrival
and receive results in the same visit. Non-NAAT POCT results
were available for all patients prior to leaving clinic; rapid
CT/NG results were available for only 21.4% (15/70; 5
males, 10 females) of patients prior to leaving clinic. Known
negative CT/NG results led to two females avoiding
presumptive treatment, and one male receiving treatment
directed at possible Mycoplasma genitalium infection causing
non-gonococcal urethritis. Non-NAAT POCTs detected more
positives than routine microscopy (TV 3 vs 2; BV 24 vs 7),
resulting in more patients receiving treatment.
Conclusions A ‘sample ﬁrst’ clinical pathway to enable
multiple POCT use was acceptable to patients and feasible in
a busy sexual health clinic, but rapid CT/NG processing time
was too long to enable POCT use. There is need for further
development to improve test processing times to enable POC
use of rapid NAATs.
INTRODUCTION
STIs, which continue to present a large public
health burden in England, with more than 400 000
STI diagnoses a year,1 are largely asymptomatic,2
resulting in long infectious periods. Regular STI
testing and treatment aim to reduce these infectious
periods and onward transmission rates but there is
presently no evidence of overall reductions in
diagnosis rates from national STI testing pro-
grammes such as the National Chlamydia Screening
Programme (NCSP).1 3
Sexual Health Clinics (SHCs) in England report
median times between testing and treatment for
Chlamydia trachomatis (CT) of 8 days,4 while the
NCSP reports 94% of CT infections being treated
within 30 days.5 Sex with new partners has been
noted in the period between testing and receiving
treatment for CT6 suggesting that, unless followed
by prompt treatment, widespread testing may have
limited impact reducing the burden of infection.
Additionally, longer durations of infection may
increase risks of clinical complications.7 Moreover,
recalling patients for treatment requires signiﬁcant
time and ﬁnancial investment for SHCs.4
Implementing rapid tests, where results are avail-
able within 2 hours of sample provision,8 as
point-of-care tests (POCTs), where tests are con-
ducted and results and treatment given within one
consultation,9 offers possibilities of deploying STI
test-and-treat strategies, enabling both rapid and per-
sonalised STI treatments while improving antibiotic
stewardship. Innovations in rapid nucleic acid ampli-
ﬁcation tests (NAATs) and non-NAATs may provide
improvements and alternatives to microscopy, the
main STI point-of-care test (POCT) available in
SHCs.10 However, there are few studies evaluating
use of rapid and POC tests in practice, including how
patients and providers respond to them, and time
taken between test, result and treatment.11 12
We performed a service evaluation of a modiﬁed,
so-called ‘sample ﬁrst’ (patients providing samples
on arrival at clinic, before clinician consultation)
clinical care pathway to assess feasibility and
acceptability of implementing POCTs for symptom-
atic patients in an SHC, and to evaluate impact of
the pathway on patient management.
Speciﬁc objectives were to assess:
1. Acceptability to patients of a ‘sample ﬁrst’ clin-
ical pathway to enable POCTuse.
2. Whether a ‘sample ﬁrst’ approach enabled a
rapid NAAT to be used as a POCT in practice.
3. Whether a ‘sample ﬁrst’ approach was feasible
for non-NAAT POCTuse in practice.
4. The impact on patient diagnosis and treatment
of multiple POCTs within a ‘sample ﬁrst’
approach.
METHODS
The service evaluation was performed between
January and April 2013 at the St George’s
University Hospitals NHS Foundation Trust Sexual
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Health Clinic. Tests were donated by manufacturers, limiting
sample size to 70 patients (35 males and 35 females). Following
review by the Interim Research Governance Lead of the Joint
Research Ofﬁce, St George’s, the project was determined as ful-
ﬁlling the criteria of a ‘service evaluation’. Ethics submission
and approval was therefore not a requirement. This manuscript
was written following Standards for Quality Improvement
Reporting Excellence (SQUIRE) guidelines (see online
supplementary material 1).13
Tests, all of which were CE-marked, included: CT/Neisseria
gonorrhoeae (CT/NG) NAAT (Cepheid GeneXpert, California,
USA) and lateral ﬂow tests for Trichomonas vaginalis (TV)
(OSOM Trichomonas Rapid Test, Sekisui Diagnostics,
Massachusetts, USA; an antigen-detection immunochromato-
graphic enzyme immunoassay) and bacterial vaginosis (BV)
(Alere VS-SENSE, Massachusetts, USA). The GeneXpert CT/
NG NAAT achieves sensitivities and speciﬁcities >97% for uro-
genital samples compared with other NAATs,14 15 and is cur-
rently widely used as a rapid test, but not a POCT.16 OSOM TV
has reported sensitivities of 88.2%–98.0% and speciﬁcities of
99.4%–100% compared with wet mount microscopy, culture or
a composite gold standard including PCR assays.17–19 The Alere
VS-SENSE BV test, an acidity test based on pH levels designed
to be used together with additional clinical data/indications such
as Amsel or Hay-Ison criteria or Nugent Gram stain,20 has
reported sensitivities of 82.3%–91% and speciﬁcities of 94.2%–
97.8% compared with pH paper.21 22 On the basis of the tests’
intention for use, clinicians were informed to use the
GeneXpert CT/NG and OSOM TV tests as diagnostic tests with
deﬁnitive results. For BV, diagnosis was based on Hay-Ison cri-
teria of vaginal ﬂora: grade III was designated BV, grades 0 and I
were designated not BV and grade II was designated mixed ﬂora
where a clinical decision to treat as BV could be made (see
online supplementary material 2). Clinicians were informed that
the VS-SENSE BV test was a pH-based assay, and as such could
be used as a diagnostic aid to complement normal clinical
diagnosis.
Criteria for inclusion in the pathway, deliberately selected to
increase likelihood of having CT/NG-positive patients to enable
worthwhile impact assessment on patient management, were:
patients aged ≥16 years; males not having passed urine in pre-
ceding 2 hours; symptomatic (males with symptoms suggestive
of urethritis; females with vaginal discharge, pelvic pain, dyspar-
eunia, intermenstrual bleeding or postcoital bleeding) or sexual
contacts of CT/NG-positive individuals. Exclusion criteria were
patients not fulﬁlling the inclusion criteria, and patients with
complex symptoms or histories.
The routine clinical pathway at the St George’s walk-in SHC
is depicted in ﬁgure 1. Brieﬂy, patients presenting to the clinic
are self-triaged at registration as asymptomatic (for an STI
check-up with no other complaints or needs) or as not asymp-
tomatic (have symptoms or other needs). Asymptomatic patients
follow a ‘quick-check’ pathway, seeing non-medical staff who
conﬁrm pathway eligibility and collect appropriate samples.
Symptomatic patients wait to have a consultation with a clin-
ician, resulting in a management plan including examination
and diagnostic tests. Microscopy is conducted to provide POCT
results for non-gonococcal urethritis (NGU) (males) and BV and
TV (females) and then treatment given based on overall clinical
diagnosis. Patients are then clinically discharged. NAAT labora-
tory results are available in 1–14 days.
The service evaluation modiﬁed ‘sample ﬁrst’ pathway is
shown in ﬁgure 2. Patients were recruited during 24 clinic ses-
sions by a dedicated senior clinician, who reviewed patients’
routine self-triage forms, approached eligible patients and
explained the modiﬁed ‘sample ﬁrst’ clinical pathway. Those
accepting the pathway provided samples at recruitment to
increase likelihood of receiving all rapid test results during their
clinic visit; had routine CT/NG NAAT laboratory testing
replaced by Cepheid CT/NG GeneXpert NAAT and also had
non-NAAT POCTs (OSOM TV and VS-SENSE BV) performed
in addition to routine culture and microscopy.
Samples were collected in the following order. For males, a
urethral swab was ﬁrst collected by nursing staff, followed by a
self-collected ﬁrst void urine (FVU) sample. Females were asked
to provide three self-collected vaginal swabs (SCVS), one each
for the CT/NG, TV and BV tests, and could choose the order in
which swabs were taken.
The following tests were performed in the clinic laboratory: CT/
NG on FVU (males) and SCVS (females) following manufacturer’s
instructions (test-time, 90 min); microscopy examination of wet-
mount of vaginal swab (females), and Gram-stained urethral
smear (males) and vaginal smear (females) (result available within
15 min) and TV and BV POCTs (test-time 15 and 5 min, respect-
ively). All CT/NG and positive BV/TV POCTresults were veriﬁed
by a senior clinician. It was not feasible to conﬁrm BV/TV POCT
negatives as results had to be read within a speciﬁc time-point.
Following sample collection, patients joined the routine clinic
queue and were seen by clinicians who were made aware of any
POCT results available at the time of consultation. In all other
respects, patients received usual clinic management, including
clinical diagnosis and treatment, health promotion and partner
notiﬁcation. Clinicians did not delay the patient pathway to
allow for the rapid test results to become available, and only
acted on results that were available at the time of ﬁnal consult-
ation, except for patients who stated at recruitment that they
wanted to wait for their CT/NG results beyond their clinical
consultation. These patients were then seen again and appropri-
ately managed according to their CT/NG rapid test results.
CT/NG, TV and BV POCT and urethral smear results were
manually entered into patients’ records. During the evaluation,
clinic staff recorded exact timings in minutes of each stage of the
‘sample ﬁrst’ pathway for each patient and waiting periods
between these, that is, time of patient arrival, triage, sample collec-
tion, clinical consultation, CT/NG test result availability, discharge
from clinic. Patient records were reviewed to determine diagnosis,
clinical care pathway duration and treatment, and to infer how
these may have differed if POCTresults had not been available.
Patients were given an anonymous unlinked feedback ques-
tionnaire at the time of agreeing to undertake the ‘sample ﬁrst’
pathway, to be completed before leaving clinic, which covered
their opinions on length of stay in clinic, providing samples on
arrival at clinic, receiving test results in the same clinical visit,
quality of service received compared with any previous visits
and whether they intended waiting for rapid CT/NG results in
case they were not available at the time of clinical diagnosis.
There was also a free-text comments box.
Statistical analyses
Speciﬁc outcome measures were:
1. Proportion of patients who responded in favour of the
‘sample ﬁrst’ approach.
2. Proportion of patients who received test results in the same
clinical visit.
3. Individual durations of patient pathway component parts
(triage, recruitment, sample collection, clinician consultation,
discharge from clinic).
425Harding-Esch EM, et al. Sex Transm Infect 2017;93:424–429. doi:10.1136/sextrans-2016-052988
Clinical
group.bmj.com on January 5, 2018 - Published by http://sti.bmj.com/Downloaded from 
Figure 1 St George’s University Hospitals NHS Foundation Trust Sexual Health Clinic clinical pathways. Symptomatic: males (symptoms of urethritis
or epididymo-orchitis): dysuria; urethral discharge; urinary discomfort, frequency, haematuria, haematospermia; scrotal lump/discomfort. Females
(symptoms of vaginal discharge or pelvic inﬂammation): vaginal discharge, vulval/vaginal discomfort; dyspareunia/pelvic pain; postcoital and/or
intermenstrual bleeding; dysuria, urinary discomfort, frequency, urgency. Contacts of gonorrhoea-positive individuals are managed as symptomatic.
Contacts of chlamydia-positive individuals are managed as asymptomatic, but see a clinician as they need treatment. MSM, men who have sex with
men; CT, Chlamydia trachomatis; NG, Neisseria gonorrhoeae; TV, Trichomonas vaginalis; FVU, ﬁrst void urine; SCVS, self-collected vaginal swab;
VVS, vulvovaginal swab; STS, serological tests for syphilis; NAAT, nucleic acid ampliﬁcation test; POCT, point-of-care test.
Figure 2 ‘Sample ﬁrst’ service evaluation patient pathways. CT, Chlamydia trachomatis; NG, Neisseria gonorrhoeae; TV, Trichomonas vaginalis; BV,
bacterial vaginosis; FVU, ﬁrst void urine; SCVS, self-collected vaginal swab; VVS, vulvovaginal swab; STS, serological tests for syphilis; NAAT, nucleic
acid ampliﬁcation test, POCT: point-of-care test.
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4. Comparisons of patient management using the modiﬁed
‘sample ﬁrst’ pathway with that assumed if the routine
pathway were followed, with regard to changes in diagnoses
of TVand BV by comparing standard wet mount microscopy
with the OSOM test, and Gram stain microscopy with the
VS-SENSE test, respectively; NGU if CT/NG POCT results
available.
RESULTS
Seventy (35 male, 35 female) symptomatic patients were tested
using the ‘sample ﬁrst’ clinical pathway (table 1). All patients
approached agreed to undertake the pathway, with no refusals,
and all stayed until they were discharged from clinic, whether or
not rapid CT/NG results were available.
Microscopy and non-NAAT POCT results were all available
before the end of patients’ consultations. However, only 15/70
(21.4%) (5 males, 10 females) were recorded as having received
their CT/NG results before leaving clinic. For patients who were
discharged before receiving their CT/NG result, the median
delay between patient discharge and CT/NG result availability
was 46 min (range 6–155).
The TV and BV non-NAAT POCTs detected more positives
than routine clinical tests did (table 1). For TV, this resulted in
one additional TV diagnosis and treatment. For BV, 11 of the 24
POCT positives (45.8%) were conﬁrmed as BV positive (7 with
microscopy grade III, 4 with mixed ﬂora designated as BV fol-
lowing clinical indicators). A further three patients were TV posi-
tive and received treatment (metronidazole) that would equally
Table 2 Anonymous feedback questionnaire responses, by duration of patient clinic visit
Time in clinic (n/N, %)
Total (N=24)<1 hour (N=10) 1–2 hours (N=11) >2 hours (N=3)
Amount of time in clinic was acceptable 9/9 (100.0) 10/10 (100.0) 1/3 (33.3) 20/22 (90.9)
‘Sample first’ approach was acceptable 9/10 (90.0) 11/11 (100.0) 3/3 (100.0) 23/24 (95.8)
Liked idea of having results in same clinical visit 8/10 (80.0) 11/11 (100.0) 3/3 (100.0) 22/24 (91.7)
Were waiting for CT/NG test results beyond clinical consultation 9/10 (90.0) 4/10 (40.0) 2/3 (66.7) 15/23 (65.2)
Found service better than at previous visits 5/9 (56.0)* 8/9 (88.9) 1/1 (100.0) 14/19 (73.7)
*The remaining 4/9 (44.4%) found the service to be the same as before.
CT/NG, Chlamydia trachomatis/Neisseria gonorrhoeae.
Table 1 Summary of test results and patient clinical pathway timings
Males Females Total
Number of patients recruited 35 35 70
Test results
CT/NG
Cepheid CT positive: N (% of total) 6 (17.1) 0 (0) 6 (8.6)
Cepheid NG positive: N (% of total) 1 (2.9) 0 (0) 1 (1.4)
Non-gonococcal urethritis
Based on Gram stain microscopy (urethral smear): N (% of male total with results) 13 (37.1) N/A 13 (37.1)
TV
Based on wet-mount microscopy: N (% of female total) N/A 2 (5.7)* 2 (5.7)*
Based on OSOM: N (% of female total) N/A 3 (8.6)* 3 (8.6)*
BV
Based on Gram stain microscopy: N (% of female total) N/A 7 (20.0)†,‡ 7 (20.0)†,‡
Based on VS-SENSE: N (% of female total) N/A 24 (68.6)†,§ 24 (68.6)†,§
Median (range) time, in minutes, spent in clinic from:
Clinic arrival to discharge from clinic 113 (59–206) 110 (59–184) 113 (59–206)
Clinical arrival to first clinical consultation 93 (45–182) 79 (32–144) 90 (32–182)
Clinic arrival to CT/NG test result being available¶ 159 (128–216) 153 (112–249) 159 (112–249)
Sample collection to discharge from clinic 71 (30–149) 75 (42–157) 74 (30–157)
Sample collection to clinical consultation 55 (7–131) 46 (16–88) 48 (7–131)
Sample collection to CT/NG test result being available¶ 107 (94–189) 106 (97–204) 107 (94–204)
Discharge from clinic to CT/NG test result being available, for patients who did not receive CT/NG while in clinic¶ 39 (6–108) 127 (120–155) 46 (6–155)
CT/NG test result received
During clinical consultation 4 8** 12
After clinical consultation, but patient waited for results before leaving clinic 1 2 3
After patient left clinic 30 25 55
*The two microscopy positives were OSOM TV positive.
†The seven microscopy positives were VS-SENSE BV positive.
‡An additional 11 were borderline BV by microscopy, of whom 6 had clinical evidence of BV.
§Two VS-SENSE BV negatives had borderline microscopy and clinical evidence of BV.
¶The time at which the CT/NG result was available was recorded for 31 patients only.
**Two females received their results but it is unknown whether they waited or not—we have assumed results were received during clinical consultation.
BV, bacterial vaginosis; CT, Chlamydia trachomatis; TV, Trichomonas vaginalis.
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have treated a BV infection. Of the remaining 10 BV POCT posi-
tives that clinically did not have BV (6 had no signs of BV and 4
had mixed ﬂora where the symptoms and signs indicated another
aetiology), 6 were treated as BV. Two females were not given pre-
sumptive treatment due to known negative CT/NG results. One
male patient diagnosed with NGU by urethral smear and negative
for CT/NG received treatment targeted at possible Mycoplasma
genitalium (MG) infection. No other treatment changes were
made based on POCTresults in men.
Of the 70 patients following the ‘sample ﬁrst’ pathway, 24
completed the anonymous questionnaire after clinic discharge
(table 2). Over 90% of those answering the survey were happy
to give samples on arrival, and liked the idea of having test
results in the same clinical visit. A number of patients expressed
satisfaction in free-text comments of the more efﬁcient service
that reduced their anxiety. All patients who were in clinic
≤2 hours found the amount of time in clinic acceptable.
DISCUSSION
This ‘sample ﬁrst’ pathway, which enabled the real-life impact of
rapid and POC test introduction into our SHC, was highly
acceptable, demonstrated by >90% of those providing feedback
in favour of giving samples on arrival and receiving results in
the same clinical visit.
This is the ﬁrst report of absolute times waited for the CT/
NG GeneXpert, as opposed to willingness to wait.16 23 Results
from microscopy and non-NAAT POCTs were all available by
time of consultation and compared with the standard clinical
pathway, resulted in increased numbers of diagnoses at ﬁrst visit,
compared with routine microscopy alone, leading to an
increased number of treatments given. This had potential bene-
ﬁts of reducing duration of infection and risk of transmission to
sexual partners.
In stark contrast, CT/NG results were available in time for
only a ﬁfth of patients, with GeneXpert processing times too
long to impact on the majority of patients’ clinical care, a
ﬁnding consistent with previous reports.12 16 Nevertheless, the
‘sample ﬁrst’ approach enabled changed patient management
for some of the 15 patients who did receive their CT/NG
results in time (two females avoided presumptive treatment and
one male received treatment targeted at presumed MG, follow-
ing negative CT/NG results), demonstrating the potential role of
POCTs in antibiotic stewardship.24
The main limitations of this evaluation are the small sample
size, and only 44.3% of patients having had accurate timings of
the pathway recorded due to a paper-based clinical notes system
in use at the time. In addition, as this was a service evaluation
rather than a research study we did not set out to assess diagnos-
tic accuracy.
The ‘sample ﬁrst’ pathway was a simpliﬁcation of the routine
clinic pathway, which led to the relative successful deployment
of POCTs. Alternative pathways that might ensure patients
receive CT/NG results during, or soon after, clinical consult-
ation25 are unlikely to be effective in our clinic given that the
median time between patient arrival and clinical consultation is
equivalent to the GeneXpert 90 min test-time, even if patients
self-collected samples prior to clinic arrival. For our clinic, an
ideal CT/NG NAAT POCT turnaround time using a ‘sample
ﬁrst’ pathway would need to be no more than approximately
30 min, given the median time between sample collection and
clinical consultation of 48 min. There are some promising tech-
nologies in development, but not yet readily available, that may
fulﬁl this requirement while maintaining high diagnostic
accuracy.11
Although we used CE-marked tests, regulatory approval does
not guarantee high accuracy,26 and the degree to which accuracy
can be compromised in the interests of reducing turnaround
time is context-dependent.27 28 The GeneXpert, already shown
to be highly accurate,14 15 is now used routinely in a number of
non-POCT settings.16 The extra TV diagnosis is consistent with
other reports of high OSOM TV test sensitivity,17 18 29 whereas
the six BV cases that were diagnosed by the POCT alone, and
consequently treated, are more difﬁcult to interpret as the few
performance evaluations of VS-SENSE use pH paper as the ref-
erence standard,21 22 and results should be interpreted together
with clinical examination.20 In our service evaluation, it would
appear that in some instances, the VS-SENSE BV POCT was
used as a diagnostic tool as opposed to as a diagnostic aid, as
had been instructed. This may have been due to the manner in
which the BV POCT result was reported on clinical notes, as
either BV POCT ‘positive’ or ‘negative’, which implies a deﬁni-
tive result. Not having a full understanding of the clinicians’
decision-making process with regard to the BV POCT result is a
limitation of this study. To help our understanding of how to
introduce new diagnostic tests in SHCs, qualitative research
investigating healthcare professionals’ views towards novel diag-
nostic technologies is warranted.
Our ﬁndings show that multiple POCTs deployed in a
‘sample ﬁrst’ SHC clinical pathway have potential to affect
patient treatment and management, with additional TV and BV
diagnoses and three patients not receiving presumptive treat-
ment. However, patients were unwilling to wait >2 hours for
CT/NG GeneXpert NAAT results, and with only 21.4% of
patients receiving their CT/NG results before leaving clinic, this
test cannot be regarded as a POCT for our clinical patient popu-
lation. New diagnostic tests with faster turnaround times,
ideally of around 30 min, without compromising on diagnostic
accuracy, are needed to enable test-and-treat strategies to be
implemented in SHCs, as well as in other STI testing settings.
Test-and-treat strategies have potential advantages such as:
immediate and accurate management of patients resulting in less
onward transmission and reduced risk of development of seque-
lae; reduced use of presumptive or inappropriate treatment thus
decreasing the risk of antimicrobial resistance development; less
patient loss to follow-up and improved partner notiﬁcation.25
However, the adoption by SHCs of POCTs that enable
test-and-treat strategies is also dependent on the cost of the
tests, and the funding structures in place. Sexual health commis-
sioning in England is complex, with regional, provider and
reimbursement type (tariff vs block) differences.30 Furthermore,
introduction of POCTs in SHCs for organisms, such as CT and
NG, which are currently being tested for on high-throughput
NAAT platforms in centralised laboratories, would require
SHCs to be convinced of the value for money of POCT intro-
duction. In these times of budget constraints, the ‘effectiveness’
of POCTs must outweigh the additional costs to SHCs.
Although an initial cost-effectiveness analysis of the CT/NG
GeneXpert in the UK SHCs provided promising results,25 the
speciﬁc ‘sample ﬁrst’ pathway we employed was not modelled.
Further cost-effectiveness analyses are required to model differ-
ent patient pathways, and assess the costs and beneﬁts of differ-
ent STI POCTs currently in development.11
This service evaluation was conducted in one SHC in London,
and the results are therefore not generalisable. Larger studies to
evaluate the clinical impact of POCTs in clinic are required, which
would in turn help to both populate the parameter inputs of cost-
effectiveness models, and provide much needed clinical effective-
ness data to support adoption of these technologies in SHCs.
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Key messages
▸ A ‘sample ﬁrst’ clinical pathway (providing samples on clinic
arrival) was acceptable, enabling successful rapid and
point-of-care test (POCT) deployment in a busy sexual health
clinic.
▸ Non-nucleic acid ampliﬁcation test (NAAT) POCT results
were available for all patients prior to leaving clinic.
▸ With only one-ﬁfth of patients receiving Chlamydia
trachomatis/Neisseria gonorrhoeae NAAT results before
leaving clinic, the GeneXpert was a rapid, not POC, test in
our clinic.
▸ ‘Sample ﬁrst’ deployment of multiple POCTs impacted
patient management, with additional Trichomonas vaginalis
and bacterial vaginosis diagnoses and three patients not
receiving presumptive treatment.
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